Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
 - EconoTimes)
NEW ORLEANS, Aug. 11, 2017 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 26, 2017 to file lead plaintiff applications in a securities class action lawsuit against Foundation Medicine, Inc. (NasdaqGS:FMI), if they purchased the Company’s shares between February 26, 2014 and November 3, 2015, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Massachusetts.
Get Help
Foundation Medicine, Inc. investors should visit us for more information about their rights at https://www.claimsfiler.com/cases/view-foundation-medicine-inc-securities-litigation\ or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
Foundation Medicine and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the likelihood that the Company would be approved for reimbursement of its tumor tests by Medicare; (ii) the Company’s progress in doing so; (iii) the Company’s robust 2015 financial guidance; (iv) the assumption of Medicare approval on which its 2015 guidance was based; and (iv) as a result of the foregoing, Foundation’s financial statements were materially false and misleading at all relevant times.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
